ArticleStem cells international2022
A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors.
Article in Stem cells international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- A Comprehensive Pan-cancer Analysis Identified that TRIB3 was Associated with Immune Cell Infiltration and Poor Prognosis.Current pharmaceutical biotechnology · 2025Article
- PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer.Theranostics · 2025Article
- Retracted: A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors.Stem cells international · 2024Article
- PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.Frontiers in oncology · 2024Article
Corrections and comments
- Retraction · 2024-01-24Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions · · See also: https://pubpeer.com/publications/DEB6366F586CCE07582DC579D8685A
- Retracted
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To understand common but distinctive systems to drive oncogenic stages in human tumors is critical for understanding disease programme and developing novel therapeutic strategies. PBRM1 is a critical gene in oncogenesis. We found that PBRM1 is upregulated in multiple cancer genes. Prognostic analyses indicated that higher PBRM1 showed better disease outcomes of head and neck squamous cell carcinoma (HNSC), KIRC, and UCEC, while poorer outcomes in KICH, skin cutaneous melanoma (SKCM), and esophageal carcinoma (ESCA). PBRM1 mutation was most frequent in renal cell carcinoma and showed better disease outcomes of pan-cancer. We also discovered that PBRM1 performance was associated with endothelial cell invasion status in COAD, HNSC, KIRC, LUAD, LUSC, OV, and PAAD, and cancer-related fibroblast invasion was observed in COAD, HNSC, KIRC, LUSC, MESO, OV, and PAAD. We also make the comparison of PBRM1's phosphorylation between normal and basic tumor systems as well as explore potential systems with distinctive functions in PBRM1-mediated oncogenesis. The analysis of pan-cancer offers us an outline of PBRM1's functions in various human cancers, which could promote a comprehensive understanding of PBRM1 in tumorigenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.